JP2015513533A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513533A5
JP2015513533A5 JP2014557802A JP2014557802A JP2015513533A5 JP 2015513533 A5 JP2015513533 A5 JP 2015513533A5 JP 2014557802 A JP2014557802 A JP 2014557802A JP 2014557802 A JP2014557802 A JP 2014557802A JP 2015513533 A5 JP2015513533 A5 JP 2015513533A5
Authority
JP
Japan
Prior art keywords
szeto
schiller
phe
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014557802A
Other languages
English (en)
Japanese (ja)
Other versions
JP6356614B2 (ja
JP2015513533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/026299 external-priority patent/WO2013123298A1/en
Publication of JP2015513533A publication Critical patent/JP2015513533A/ja
Publication of JP2015513533A5 publication Critical patent/JP2015513533A5/ja
Application granted granted Critical
Publication of JP6356614B2 publication Critical patent/JP6356614B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014557802A 2012-02-17 2013-02-15 薬剤のミトコンドリア輸送のためのナノ粒子 Expired - Fee Related JP6356614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600088P 2012-02-17 2012-02-17
US61/600,088 2012-02-17
PCT/US2013/026299 WO2013123298A1 (en) 2012-02-17 2013-02-15 Nanoparticles for mitochondrial trafficking of agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018008528A Division JP6612905B2 (ja) 2012-02-17 2018-01-23 薬剤のミトコンドリア輸送のためのナノ粒子

Publications (3)

Publication Number Publication Date
JP2015513533A JP2015513533A (ja) 2015-05-14
JP2015513533A5 true JP2015513533A5 (enExample) 2015-10-08
JP6356614B2 JP6356614B2 (ja) 2018-07-11

Family

ID=48984733

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014557802A Expired - Fee Related JP6356614B2 (ja) 2012-02-17 2013-02-15 薬剤のミトコンドリア輸送のためのナノ粒子
JP2018008528A Expired - Fee Related JP6612905B2 (ja) 2012-02-17 2018-01-23 薬剤のミトコンドリア輸送のためのナノ粒子
JP2019198467A Expired - Fee Related JP6904606B2 (ja) 2012-02-17 2019-10-31 薬剤のミトコンドリア輸送のためのナノ粒子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018008528A Expired - Fee Related JP6612905B2 (ja) 2012-02-17 2018-01-23 薬剤のミトコンドリア輸送のためのナノ粒子
JP2019198467A Expired - Fee Related JP6904606B2 (ja) 2012-02-17 2019-10-31 薬剤のミトコンドリア輸送のためのナノ粒子

Country Status (5)

Country Link
US (2) US10416167B2 (enExample)
EP (1) EP2814496B1 (enExample)
JP (3) JP6356614B2 (enExample)
ES (1) ES2669561T3 (enExample)
WO (1) WO2013123298A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CA2931638A1 (en) 2013-12-12 2015-06-18 University Of Georgia Research Foundation, Inc. Prodrug for release of cisplatin and cyclooxygenase inhibitor
WO2015123576A2 (en) * 2014-02-17 2015-08-20 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
WO2015138992A1 (en) * 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015173818A1 (en) 2014-05-13 2015-11-19 B.G. Negev Technologies And Applications Ltd. Peptide-polypeptide co-assembled nanoparticles for drug delivery
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
WO2016076924A2 (en) * 2014-07-25 2016-05-19 Wake Forest University Fas inhibitors and methods associated therewith
US20170216219A1 (en) * 2014-08-04 2017-08-03 University Of Georgia Research Foundation, Inc. Therapeutic nanoparticles for accumulation in the brain
US10450289B2 (en) 2015-06-08 2019-10-22 University of Pittsburgh—of the Commonwealth System of Higher Education Substituted β-lapachones for treating cancer
WO2017095751A1 (en) * 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20180011346A1 (en) * 2016-07-05 2018-01-11 Nanoco Technologies Ltd. Probe for targeting and manipulating mitochondrial function using quantum dots
US11090389B2 (en) 2016-10-13 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Mitochondrially targeted PARP inhibitor, and uses thereof
ES2952779T3 (es) 2017-05-18 2023-11-06 Modernatx Inc ARN mensajero modificado que comprende elementos de ARN funcionales
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
WO2019104160A2 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7424976B2 (ja) 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
EP3735270A1 (en) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
US20210268128A1 (en) * 2018-07-10 2021-09-02 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent nanoparticles and imaging uses
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
EP3849595B1 (en) 2018-09-13 2025-11-19 ModernaTX, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
US20220401584A1 (en) 2018-09-14 2022-12-22 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP3856233A1 (en) 2018-09-27 2021-08-04 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
KR102104068B1 (ko) * 2018-12-19 2020-04-23 가톨릭대학교 산학협력단 미토콘드리아 표적능을 갖는 고분자 및 상기 고분자를 이용한 약물 전달용 조성물
CN114375190A (zh) 2019-05-08 2022-04-19 阿斯利康(瑞典)有限公司 用于皮肤和伤口的组合物及其使用方法
CA3184474A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
US20240226025A1 (en) 2021-03-24 2024-07-11 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20220370636A1 (en) * 2021-05-05 2022-11-24 University Of South Florida Nicotinamide adenine dinucleotide activator and use thereof
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
CN114904005B (zh) * 2022-05-24 2024-02-02 浙江大学医学院附属第一医院 一种低密度三苯基膦修饰的体内长循环药物制剂及其制备方法和应用
MA71619A (fr) 2022-07-26 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
AU2024265267A1 (en) 2023-05-03 2025-11-20 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217864B1 (en) 1996-02-23 2001-04-17 The Regents Of The University Of California Method for targeted degradation of intracellular proteins in vivo or ex vivo
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6753154B1 (en) 1998-06-26 2004-06-22 The Regents Of The University Of California Human AZU-1 gene, variants thereof and expressed gene products
WO2000000503A1 (en) 1998-06-26 2000-01-06 The Regents Of The University Of California Human az-1 gene, variants thereof and expressed gene products
WO2005019232A1 (en) 2003-08-22 2005-03-03 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US20050153913A1 (en) 2001-04-10 2005-07-14 Kosak Kenneth M. Nucleic acid carrier compositions and methods for their synthesis
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
EP2430923A1 (en) 2002-06-05 2012-03-21 Genentech, Inc. Compositions and methods for liver growth and liver protection
JP5107573B2 (ja) 2003-04-25 2012-12-26 ザ ペン ステイト リサーチ ファウンデーション 増殖抑制性脂質由来生物活性化合物の全身送達方法およびシステム
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7728036B2 (en) 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
CN1839142B (zh) * 2003-08-22 2010-06-16 澳新制药公司 用作靶向线粒体的抗氧化剂的线粒体醌衍生物
ZA200605822B (en) 2003-12-16 2009-05-27 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
US7393924B2 (en) 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
AU2005213965B2 (en) 2004-02-12 2009-11-19 Lexicon Pharmaceuticals, Inc. Gene disruptions, compositions and methods relating thereto
WO2005107818A2 (en) 2004-04-30 2005-11-17 University Of Florida Nanoparticles and their use for multifunctional bioimaging
EP1744620A2 (en) 2004-05-12 2007-01-24 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
US20080051323A1 (en) 2004-08-21 2008-02-28 Kosak Kenneth M Chloroquine drug compositions and methods for their synthesis
US20060040879A1 (en) 2004-08-21 2006-02-23 Kosak Kenneth M Chloroquine coupled nucleic acids and methods for their synthesis
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
JP2008510488A (ja) 2004-08-25 2008-04-10 ジェネンテック・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
ZA200704338B (en) 2004-10-29 2009-03-25 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
FR2877571B1 (fr) * 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
EP1838353A2 (en) 2005-01-21 2007-10-03 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
EP1846355B1 (en) 2005-01-27 2009-12-16 Ocean Nutrition Canada Limited Fatty acid-benzenediol derivatives and methods of making and using thereof
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
MX2007012157A (es) 2005-04-01 2008-03-14 Intezyne Technologies Llc Micelas polimericas para suministro de farmacos.
US7725169B2 (en) 2005-04-15 2010-05-25 The Board Of Trustees Of The University Of Illinois Contrast enhanced spectroscopic optical coherence tomography
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
AU2006249323B2 (en) 2005-05-27 2012-08-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2008054341A2 (en) 2005-06-20 2008-05-08 The Research Foundation Of State University Of New York Method of bioimaging using nanocrystals of fluorescent dyes
US20060286082A1 (en) 2005-06-20 2006-12-21 Kurzweil Raymond C Systems and methods for generating biological material
AU2006272586A1 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Use of heat shock to treat ocular disease
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20100144641A1 (en) 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2008048288A2 (en) 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20110172826A1 (en) 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
WO2007080591A2 (en) 2006-01-11 2007-07-19 Technion Research & Development Foundation Ltd. Adult stem cell-derived connective tissue progenitors for tissue engineering
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
JP2009528294A (ja) 2006-02-23 2009-08-06 エリモス・ファーマスーティカルズ・エルエルシー インフルエンザウイルス感染症の治療方法
CA2648243C (en) 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20080069857A1 (en) 2006-04-12 2008-03-20 Yoon Yeo Compositions And Methods For Inhibiting Adhesions
US8449915B1 (en) * 2006-04-17 2013-05-28 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US8297959B2 (en) 2006-05-03 2012-10-30 Terapia Celular, Ln, Inc. Systems for producing multilayered particles, fibers and sprays and methods for administering the same
WO2007140483A2 (en) 2006-05-31 2007-12-06 The Trustees Of The Boston University Films and particles
US7671095B2 (en) 2006-05-31 2010-03-02 The Trustees Of The Boston University Films and particles
US20100196280A1 (en) 2006-06-08 2010-08-05 Katrin Claudia Fischer Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
AU2007305220A1 (en) 2006-07-28 2008-04-10 Genentech, Inc. Knockout mice for different genes and their use for gene characterizatio
EP2049520A4 (en) 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
CN101547689B (zh) 2006-10-02 2014-02-26 埃里莫斯医药品有限公司 通过醚键和氨基甲酸酯键四取代的ndga衍生物、它们的合成方法和药学用途
EP2082052A2 (en) 2006-11-14 2009-07-29 Genentech, Inc. Knockout mice for pro1105, pro1279 or pro1783 coding genes
WO2008091465A2 (en) 2006-12-21 2008-07-31 Wayne State University Peg and targeting ligands on nanoparticle surface
JP2010513526A (ja) 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
CA2676323A1 (en) 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel methods and reagents directed to production of cells
US20110200579A1 (en) 2007-01-23 2011-08-18 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2008147481A1 (en) 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery
WO2008106646A2 (en) 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080299177A1 (en) 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
US20080294089A1 (en) 2007-06-06 2008-11-27 Biovaluation & Analysis, Inc. Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
US20090018078A1 (en) 2007-07-09 2009-01-15 Vinod Labhasetwar Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same
US20110008304A1 (en) 2007-07-09 2011-01-13 Kansas State University Research Foundation Use of cells to facilitate targeted delivery of nanoparticle therapies
US20110038939A1 (en) 2007-07-16 2011-02-17 Northeastern University Therapeutic stable nanoparticles
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
EP2197890A1 (en) * 2007-09-07 2010-06-23 Gencia Corporation Mitochondrial compositions and uses thereof
EP2205225A4 (en) * 2007-10-03 2013-09-18 Jncasr Bangalore INTRINSIC FLUORESCENCE CARBON NANOSPHERES AND PROCESS FOR PRODUCING THE SAME
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
US20110045081A1 (en) 2007-10-12 2011-02-24 Benedikt Steitz Magnetic, paramagnetic and/or superparamagnetic nanoparticles
US7935782B2 (en) 2007-11-05 2011-05-03 Vanderbilt University Multifunctional degradable nanoparticles with control over size and functionalities
US20110274620A1 (en) 2007-11-05 2011-11-10 Harth Eva M Multifunctional degradable nanoparticles with control over size and functionalities
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
US8563066B2 (en) 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
US20090169521A1 (en) 2007-12-31 2009-07-02 Technion Research & Development Foundation Ltd. Vascularized cardiac tissue and methods of producing and using same
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
MX2011000545A (es) 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
KR101368736B1 (ko) 2008-09-25 2014-03-05 인비보 테라퓨틱스 코포레이션 척수 외상, 염증, 및 면역 질환: 치료제의 국소적 제어 방출
JP2012505243A (ja) 2008-10-09 2012-03-01 ノースイースタン・ユニバーシティ 多機能の自己集合性高分子ナノシステム
US8568363B2 (en) 2008-10-31 2013-10-29 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8563012B2 (en) 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2010056145A1 (ru) * 2008-11-12 2010-05-20 Общество С Ограниченной Ответственностью "Митотехнология" Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
CA2732686C (en) 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8273373B2 (en) 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
US20120027681A1 (en) 2009-03-11 2012-02-02 Northeastern University Low-Aspect Ratio Carbon Nanostructures
US8685538B2 (en) 2009-03-25 2014-04-01 Northeastern University Stable polyelectrolyte coated nanoparticles
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
BRPI0924549A2 (pt) 2009-06-12 2016-04-26 Amrita Vishwa Vidyapeetham University nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
US20100331819A1 (en) 2009-06-24 2010-12-30 Abbott Cardiovascular Systems Inc. Drug Delivery System and Method of Treatment of Vascular Diseases Using Photodynamic Therapy
KR101609641B1 (ko) 2009-07-28 2016-04-07 삼성전자주식회사 무선통신 시스템에서 자동 이웃 관계 구성 및 최적화를 위한 장치 및 방법
CN102791294A (zh) * 2009-12-16 2012-11-21 布里格姆妇女医院股份有限公司 用于多种药物递送的粒子
US20110203013A1 (en) 2010-02-17 2011-08-18 Pioneer Hi Bred International Inc Delivering compositions of interest to plant cells
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
US9149618B2 (en) 2010-03-17 2015-10-06 Nanomed Skincare, Inc. Built-in non-verbal instructional device integratable to applicators
US20130164851A1 (en) 2010-03-26 2013-06-27 Alnylam Pharmaceuticals, Inc. Gene amplification and transfection methods and reagents related thereto
EP3072961A1 (en) 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
ES2952389T3 (es) 2010-06-04 2023-10-31 Hough Ear Inst Composición y método de regeneración o reemplazo de células ciliadas sensoriales del oído interno
US9284188B2 (en) 2010-09-03 2016-03-15 The Regents Of The University Of California Cytosolic delivery of materials with endosome-disrupting colloids
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
US9642925B2 (en) 2010-12-07 2017-05-09 Sanford Research/USD Magnetic nanoparticle formulations, methods for making such formulations, and methods for their use
US20120177701A1 (en) 2010-12-31 2012-07-12 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
US20130136786A1 (en) 2011-02-10 2013-05-30 Sanford-Burnham Medical Research Institute Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
US9468670B2 (en) 2011-04-01 2016-10-18 Texas A&M University System Melatonin-based treatment and diagnosis of bile duct disease
CA2832443C (en) 2011-04-06 2020-08-25 The Board Of Regents Of The University Of Texas System Modulating bacterial mam polypeptides in pathogenic disease
US20120263793A1 (en) 2011-04-14 2012-10-18 Franco Vitaliano Bio-nano-plasmonic elements and platforms
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP6170047B2 (ja) * 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
WO2014124425A1 (en) 2013-02-11 2014-08-14 University Of Georgia Research Foundation, Inc. Generation of functional dendritic cells

Similar Documents

Publication Publication Date Title
JP2013172734A5 (enExample)
JP2016525888A5 (enExample)
JP2015514395A5 (enExample)
JP2017048194A5 (enExample)
JP2010534684A5 (enExample)
JP2014513951A5 (enExample)
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
WO2014139476A8 (zh) Rsv融合蛋白的表位以及识别其的抗体
JP2010143932A5 (enExample)
JP2011168603A5 (enExample)
JP2014519662A5 (enExample)
JP2014513484A5 (enExample)
JP2010065037A5 (enExample)
JP2010265269A5 (enExample)
HK1205746A1 (en) Interleukin-10 polypeptide conjugates and their uses
WO2013000922A9 (en) Ccr2 antagonist peptides
MX2016002937A (es) Vacuna oncologica.
JP2013539454A5 (enExample)
JP2015533791A5 (enExample)
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
JP2014028813A5 (enExample)
CY1121083T1 (el) Αντιμικροβιακο πεπτιδιο και οι χρησεις αυτου
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112016012306A2 (pt) peptídeos ricos em prolina para proteção contra s. pneumoniae